Mixed Cues for Pharma: Semaglutide Patent Expiry Ignites Price War

The patent expiry for semaglutide, a key weight-loss and diabetes drug, has triggered a price war in India. Innovator Novo Nordisk has cut prices for Ozempic and Wegovy, paving the way for cheaper generics. This shift is expected to broaden access to these drugs but also raises concerns about potential misuse and increased regulatory scrutiny.

This development is significant for the Indian pharmaceutical sector as it signals a major disruption in a high-growth therapeutic area. The entry of generics will intensify competition, potentially compressing margins for all players, but also expanding the overall market size. It highlights the ongoing trend of patent cliffs impacting drug pricing and market dynamics.

Indian pharmaceutical companies like Lupin, Dr. Reddy's, Sun Pharma, and Cipla, which have strong generic capabilities or existing diabetes portfolios, will face mixed impacts. While they stand to gain from increased market access and potential generic launches, they will also contend with significant pricing pressure. Companies with robust R&D for biosimilars or complex generics might be better positioned.

Traders should closely watch for announcements from Indian pharma companies regarding their plans for generic semaglutide launches and pricing strategies. Regulatory updates on the use and monitoring of these drugs will also be crucial. Observe the volume growth in this segment to gauge the market expansion versus price erosion impact on overall revenue for these companies.

• •Semaglutide has lost patent protection in India.
• •Novo Nordisk has cut prices of Ozempic and Wegovy.
• •Cheaper generics are expected to widen access to weight-loss and diabetes drugs.
• •Concerns over misuse of these drugs are rising, prompting regulatory scrutiny.